Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
George K. K. Lau, Ming‐Liang He, Daniel Y. T. Fong, Angeline Bartholomeusz, Wing‐yan Au, Albert K. W. Lie, Stephen Locarnini, Raymond Liang – 30 December 2003 – Exacerbation of hepatitis B virus (HBV) is a serious cause of morbidity and mortality in hepatitis B surface antigen (HBsAg)‐positive patients undergoing transplantation. Our aim was to evaluate the effectiveness of lamivudine to prevent hepatitis due to exacerbation of HBV in HBsAg‐positive patients treated with allogeneic hematopoietic cell transplantation.